Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.9M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
19.9M
-
Shares change
-
-1.32M
-
Total reported value, excl. options
-
$114M
-
Value change
-
-$17.5M
-
Put/Call ratio
-
1.28
-
Number of buys
-
54
-
Number of sells
-
-58
-
Price
-
$5.75
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q4 2024
135 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q4 2024.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.9M shares
of 27.9M outstanding shares and own 71.48% of the company stock.
Largest 10 shareholders include Krensavage Asset Management, LLC (2.12M shares), FARALLON CAPITAL MANAGEMENT LLC (2.11M shares), BlackRock, Inc. (2.04M shares), VANGUARD GROUP INC (1.98M shares), MORGAN STANLEY (1.22M shares), RA CAPITAL MANAGEMENT, L.P. (1.04M shares), MARSHALL WACE, LLP (930K shares), MILLENNIUM MANAGEMENT LLC (897K shares), ACADIAN ASSET MANAGEMENT LLC (849K shares), and RENAISSANCE TECHNOLOGIES LLC (498K shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.